Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesetaxel PK and QTc Study in Advanced Solid Tumors
NCT04312282Phase 1Terminated
- Sponsor
- Odonate Therapeutics
- Start
- Mar 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tesetaxel in solid tumor (advanced stage) (4 cohorts), sponsored by Odonate Therapeutics. Primary endpoints: Change from baseline in Fridericia's corrected QT interval at 3 weeks, Maximum observed plasma concentration at 6 weeks and 2 more. Started Mar 2020; status: terminated.
02
Drugs
tesetaxel
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04312282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04312282.